Resources from the same session
158MO - Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study
Presenter: Marniza Binti Saad
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
159MO - Low-dose abiraterone with fatty food versus standard dose abiraterone in metastatic castration-resistant prostate cancer
Presenter: Suboor Shaherose
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
160MO - Concomitant medication (conmed) interactions with novel hormonal agents (NHAs) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Ying Zhong
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
161MO - Efficacy and safety of relugolix in Asian men with advanced prostate cancer (APC): A subgroup analysis from the randomized, phase III HERO study versus leuprolide
Presenter: Dingwei Ye
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 158MO, 159MO, 160MO and 161MO
Presenter: Deborah Mukherji
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Deborah Mukherji
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
136MO - Efficacy and safety of pembrolizumab (pembro) monotherapy in East Asian patients (pts) with urothelial carcinoma (UC) in KEYNOTE-045 or KEYNOTE-052
Presenter: Ravindran Kanesvaran
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
137MO - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Longer-term follow-up from the Asian subgroup of the JAVELIN Bladder 100 trial
Presenter: Masatoshi Eto
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
138MO - A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin C vs intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC)
Presenter: Karandeep Guleria
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 136MO, 137MO and 138MO
Presenter: Eiji Kikuchi
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast